Acadian Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Acadian Asset Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.79M	Buy	1,038,797 +311,482	+43%	+$1.89M	﹤0.01%	883
2026 Q1	$5.57M	Sell	727,315 -9,425	-1%	-$87.4K	0.01%	681
2025 Q4	$8.33M	Buy	736,740 +196,099	+36%	+$2M	0.01%	521
2025 Q3	$4.97M	Sell	540,641 -22,739	-4%	-$165K	0.01%	644
2025 Q2	$3.87M	Buy	563,380 +218,819	+64%	+$1.17M	0.01%	647
2025 Q1	$989K	Buy	344,561 +308,854	+865%	+$1.13M	﹤0.01%	939
2024 Q4	$167K	Sell	35,707 -153,254	-81%	-$565K	﹤0.01%	1284
2024 Q3	$674K	Buy	+188,961	New	+$1.4M	﹤0.01%	1014
2021 Q2	–	Sell	-3,471	Closed	-$41K	–	2070
2021 Q1	$41K	Buy	+3,471	New	+$42.9K	﹤0.01%	1870
2020 Q4	–	Sell	-1,881	Closed	-$15K	–	2254
2020 Q3	$15K	Buy	+1,881	New	+$22.7K	﹤0.01%	2105

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management's FULC Position: Q2 2026 in Review

Acadian Asset Management increased its Fulcrum Therapeutics (FULC) stake by 43% in Q2 2026, buying an estimated $1.89M and bringing the position to 1,038,797 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Acadian Asset Management first reported a position in FULC in Q3 2020 and has held it in 10 quarters since. The position peaked at $8.33M in Q4 2025. 98 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Acadian Asset Management held 1,038,797 shares of Fulcrum Therapeutics worth $3.79M as of Q2 2026.
Acadian Asset Management bought 311,482 Fulcrum Therapeutics shares in Q2 2026, an estimated $1.89M.
Fulcrum Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #883 holding.
Acadian Asset Management first reported a position in Fulcrum Therapeutics in Q3 2020 and has held it in 10 quarters since.
Acadian Asset Management's Fulcrum Therapeutics position peaked at $8.33M in Q4 2025.
98 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.